Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

AstraZeneca

Lynparza could generate blockbuster sales as a new treatment option that isn't hormone-based.

FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck

Shares of AstraZeneca AZN, +0.22% gained 0.7% and Merck & Co. Inc.'s stock MRK, -2.72% was up 0.7% in premarket trading on Wednesday after the companies said the Food and Drug Administration had approved their cancer drug Lynparza for certain patients with prostate cancer.

AstraZeneca and Merck's Lynparza gets FDA approval for prostate cancer

CAMBRIDGE, Mass., May  20, 2020  (GLOBE NEWSWIRE) --  Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1/1b study of SRF617 and will be evaluated in patients with solid tumors, with a focus on patients with gastric cancer and those who have developed resistance to checkpoint inhibition — both areas of high unmet need. 

Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients

British pharmaceutical company, AstraZeneca (LON: AZN) collaborated with the U.S-based Merck & Co. (NYSE: MRK) on Lynparza drug as a treatment option for prostate cancer.

U.S. FDA approves AstraZeneca and Merck’s Lynparza as a treatment for prostate cancer

Boston Scientific

Salesforce

Elanco Animal Health Inc

Fidelity National Information

Lyft

David Carlson (Trades, Portfolio)’s Elfun Trusts bought shares of the following stocks in both the fourth quarter of 2019 and the first quarter of 2020.

7 Stocks Elfun Trusts Continues to Buy

Merck’s stock has underperformed the broader markets as well as some of its peers over the last few weeks. While Merck’s stock grew 20% since the recent lows of March 23, the S&P 500 gained 26%.

Merck’s Stock Headed To $100?

Merck (MRK) announces positive data from several cancer studies evaluating Keytruda across multiple indications.

Merck's (MRK) Keytruda Successful in Several Cancer Studies

MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Stefan Oschmann on Q1 2020 Results - Earnings Call Transcript

Keytruda's path to becoming the world's top-selling drug looks much smoother following its latest clinical trial success.

Merck's Top Cancer Therapy Takes Another Big Leap Forward

AbbVie

The pharmaceutical companies have not been immune to the current coronavirus crisis, although they have fared much better than the broader markets. While Merck’s stock has declined 9% since early February, after the WHO declared the coronavirus a global health emergency.

After Allergan Acquisition Is AbbVie A Better Buy Compared To Merck?

With increasing life expectancies and aging global populations comes higher prevalence of neurodegenerative disease. Merck is betting big on being the pharma company of the future.

Merck Just Made a Gamble That Smart Investors Should Bet on Too

German healthcare and chemicals company Merck KGaA  flagged that a slight decline in operating earnings was on the cards this year as the coronavirus pandemic could place a significant burden on the global economy.

Merck KGaA says profit could slip in 2020

Merck stock advanced 19% in all of 2019. Meanwhile shares of other pharmaceutical companies grabbed smaller, single-digit percentage gains.

Is Merck Stock A Buy As Coronavirus Worries Shake The Dow Jones Giant?

Gilead Sciences

Bristol-Myers

Clovis Oncology

Despite a busy few months with emergency use authorizations due to coronavirus, the Food and Drug Administration is expected to approve several new drugs in May.

From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now

Allergan

Grifols, S.A.

Jazz Pharmaceuticals

Novo Nordisk

Sanofi

Zoetis

Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.

Why These 8 Pharma Stocks Are Outplaying 90% Of The Stock Market

The pharmaceutical giant beat earnings estimates for the 25th consecutive quarter, and the stock is relatively cheap.

Merck Beats on Earnings, Stock Stays Below 200-Day SMA

Merck & Company (NYSE:MRK) reported first quarter earnings results on April 28. Results for the company have been solid over the past year or so, but the most recent quarter was especially strong.

Thoughts on Merck’s Strong First Quarter

A new, more convenient dosing schedule favors Keytruda.

Did Merck Just Receive a Gift From the FDA?

Merck & Co., Inc. (NYSE: MRK) shares came under pressure in Tuesday's session after the pharma company lowered its full-year guidance.

Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut

The company posted solid financial results, but its shares dropped due to its less-optimistic outlook.

Merck Reports First-Quarter Results, Lowers Guidance

Merck & Co., Inc. (MRK) CEO Ken Frazier on Q1 2020 Results - Earnings Call Transcript

Merck (MRK) earnings for the pharmaceutical company's first quarter of 2020 have MRK stock falling Tuesday despite beating estimates.
The post Merck Earnings: Why MRK Stock Is 3% Lower Despite Q1 Beats appeared first on InvestorPlace.

Merck Earnings: Why MRK Stock Is 3% Lower Despite Q1 Beats

Pfizer

Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc.

Why Pfizer and Merck Earnings Are Slowing the Dow

The big pharma company delivered strong revenue and earnings growth in Q1. But investors were more concerned about something else.

Why Merck's Q1 Update Disappointed Investors Despite Beating Wall Street Estimates

Merck & Co Inc  said on Tuesday it expects the coronavirus pandemic to reduce 2020 sales by more than $2 billion, and the U.S. drugmaker lowered its profit forecast as a big drop in doctors' office visits during the outbreak will take  a hefty toll, sending its shares down more than 3%.

News for Merck Stock (MRK)